Additional Information Request News Today

Interim Results for the six months ended 30 June 2021FDA Review Progressing With Response Anticipated in the Second Half of the YearSuccessful Launch of Global Pharma Services BusinessOvarian Cancer Clinical

Investegate announcements from Angle PLC, Update on submission for FDA clearance

The group is seeking approval for its Parsortix system to be used with metastatic breast cancer patients in the US

Proactive headlines: Pelatro, IQ-AI, Samarkand… A look at some of todays main headlines from the Proactive newswire Pelatro PLC (LON:PTRO) has secured contracts worth roughly US$200,000 for additional modules from existing customers. IQ-AI Limited (LON:IQAI) subsidiary Imaging Biometrics’ said its brain tumour imaging platform has been by purchased by the Los Angeles County Hospital. Samarkand Group PLC (LON:SMK) said it has formally opened its new office in Tokyo to serve the Japanese mark...

      ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, today announces audited preliminary results for the year ended 31 December 2020.     · Full De Novo Submission made in September 2020 for US Food and Drug Administration (FDA) clearance of the Parsortix ® system for capturing and harvesting circulating tumour cells from metastatic breast cancer patients -  FDA Administrative Review complete and Substantive Revi...

ANGLE plc: Angle PLC Announces Update on submission for FDA clearance UPDATE ON SUBMISSION FOR FDA CLEARANCE OF THE PARSORTIX SYSTEM Additional Information Request received from FDA as expected and ANGLE response being prepared in line with expected timescales FDA has indicated its review processes for non COVID-19 devices are currently slower than usual due to COVID-19 pandemic priorities GUILDFORD, SURREY / ACCESSWIRE / March 4, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid ...